nach oben

Pathology & Oncology Research

Erschienen in:

01.07.2014 | Research

Complexity in Regulation of microRNA Machinery Components in Invasive Breast Carcinoma

verfasst von: Sun Young Kwon, Jae-ho Lee, Bora Kim, Jong-Wook Park, Taeg Kyu Kwon, Sun Hee Kang, Shin Kim

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Altered expression of microRNA (miRNA) machinery components may play an important role in breast cancer progression. The objective of the current study was to evaluate Drosha, the DiGeorge syndrome critical region gene 8 (DGCR8), Dicer, and Argonaute 2 (AGO2) mRNA expression in invasive breast carcinoma (IBC) and to assess the value of clinical parameters on their expression. By using quantitative real-time PCR, we examined the expression of the four miRNA machinery components in 52 breast tumor tissues which are diagnosed as invasive ductal carcinoma and adjacent non-neoplastic tissues. In the present study, decreased mRNA expression levels of major miRNA machinery components were observed in IBC. The altered mRNA expression levels of DGCR8 and AGO2 are positively correlated with to each other. This study revealed for the first time that expression alterations of DGCR8 are significantly associated with estrogen receptor and Ki-67 status in IBC. Moreover, AGO2 mRNA expression level was significantly correlated with N stage. These results provided evidences that down-regulated the four miRNA machinery components may play an important role in breast pathobiology and that DGCR8 and AGO2 might be associated with important clinical factors.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. doi:10.1002/ijc.21004 PubMedCrossRef

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220 PubMedCrossRef

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093 PubMedCrossRef

Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568–2581. doi:10.1200/JCO.2007.13.1748 PubMedCrossRef

Diaz LK, Cryns VL, Symmans WF, Sneige N (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14(6):419–430. doi:10.1097/PAP.0b013e3181594733 PubMedCrossRef

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874. doi:10.1073/pnas.191367098 PubMedCentralPubMedCrossRef

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174–183. doi:10.1016/S1470-2045(09)70262-1 PubMedCrossRef

Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working G (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664. doi:10.1093/jnci/djr393 PubMedCentralPubMedCrossRef

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297PubMedCrossRef

10.

Papachristou DJ, Korpetinou A, Giannopoulou E, Antonacopoulou AG, Papadaki H, Grivas P, Scopa CD, Kalofonos HP (2011) Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Arch Int J Pathol 459(4):431–440. doi:10.1007/s00428-011-1119-5 CrossRef

11.

Mockenhaupt S, Schurmann N, Grimm D (2011) When cellular networks run out of control: global dysregulation of the RNAi machinery in human pathology and therapy. Prog Mol Biol Transl Sci 102:165–242. doi:10.1016/B978-0-12-415795-8.00006-4 PubMedCrossRef

12.

Lee Y, Han J, Yeom KH, Jin H, Kim VN (2006) Drosha in primary microRNA processing. Cold Spring Harb Symp Quant Biol 71:51–57. doi:10.1101/sqb.2006.71.041 PubMedCrossRef

13.

Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R (2004) The Microprocessor complex mediates the genesis of microRNAs. Nature 432(7014):235–240. doi:10.1038/nature03120 PubMedCrossRef

14.

Tijsterman M, Plasterk RH (2004) Dicers at RISC; the mechanism of RNAi. Cell 117(1):1–3PubMedCrossRef

15.

Sand M, Skrygan M, Georgas D, Arenz C, Gambichler T, Sand D, Altmeyer P, Bechara FG (2012) Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog 51(11):916–922. doi:10.1002/mc.20861 PubMedCrossRef

16.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641–2650. doi:10.1056/NEJMoa0803785 PubMedCentralPubMedCrossRef

17.

Kim B, Lee JH, Park JW, Kwon TK, Baek SK, Hwang I, Kim S (2013) An essential microRNA maturing microprocessor complex component DGCR8 is up-regulated in colorectal carcinomas. Clin Exp Med. doi:10.1007/s10238-013-0243-8

18.

Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Leon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C (2009) Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 101(4):673–683. doi:10.1038/sj.bjc.6605193 PubMedCentralPubMedCrossRef

19.

Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS (2011) Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 47(1):138–150. doi:10.1016/j.ejca.2010.08.007 PubMedCrossRef

20.

Passon N, Gerometta A, Puppin C, Lavarone E, Puglisi F, Tell G, Di Loreto C, Damante G (2012) Expression of Dicer and Drosha in triple-negative breast cancer. J Clin Pathol 65(4):320–326. doi:10.1136/jclinpath-2011-200496 PubMedCrossRef

21.

Yan M, Huang HY, Wang T, Wan Y, Cui SD, Liu ZZ, Fan QX (2012) Dysregulated expression of dicer and drosha in breast cancer. Pathol Oncol Res 18(2):343–348. doi:10.1007/s12253-011-9450-3 PubMedCrossRef

22.

Khoshnaw SM, Rakha EA, Abdel-Fatah TM, Nolan CC, Hodi Z, Macmillan DR, Ellis IO, Green AR (2012) Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat 135(2):403–413. doi:10.1007/s10549-012-2169-3 PubMedCrossRef

23.

Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R (2006) Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 169(5):1812–1820. doi:10.2353/ajpath.2006.060480 PubMedCentralPubMedCrossRef

24.

Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R, Fujii Y (2006) RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res 12(24):7322–7328. doi:10.1158/1078-0432.CCR-06-0515 PubMedCrossRef

25.

Martin MG, Payton JE, Link DC (2009) Dicer and outcomes in patients with acute myeloid leukemia (AML). Leuk Res 33(8):e127. doi:10.1016/j.leukres.2009.02.003 PubMedCrossRef

26.

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481PubMed

27.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984 PubMedCrossRef

28.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101–1108PubMedCrossRef

29.

Shen J, Stass SA, Jiang F (2012) MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. doi:10.1016/j.canlet.2012.11.001

30.

Li PY, He FC, Zhou GQ (2011) Association of human microRNA related genetic variations with cancer. Yi chuan = Hereditas/Zhongguo yi chuan xue hui bian ji 33(8):870–878PubMedCrossRef

31.

Schmittgen TD (2008) Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med 12(5B):1811–1819. doi:10.1111/j.1582-4934.2008.00483.x PubMedCentralPubMedCrossRef

32.

Han L, Zhang A, Zhou X, Xu P, Wang GX, Pu PY, Kang CS (2010) Downregulation of Dicer enhances tumor cell proliferation and invasion. Int J Oncol 37(2):299–305PubMed

33.

Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Muller BM, Wirtz R, Chekerov R, Weichert W, Sinn B, Mucha C, Elwali NE, Schafer R, Dietel M, Denkert C (2010) Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol 220(3):382–391. doi:10.1002/path.2658 PubMed

34.

Cheng C, Fu X, Alves P, Gerstein M (2009) mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol 10(9):R90. doi:10.1186/gb-2009-10-9-r90 PubMedCentralPubMedCrossRef

35.

Erson AE, Petty EM (2009) miRNAs and cancer: new research developments and potential clinical applications. Cancer Biol Ther 8(24):2317–2322PubMedCrossRef

36.

Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG (2010) microRNA, cell cycle, and human breast cancer. Am J Pathol 176(3):1058–1064. doi:10.2353/ajpath.2010.090664 PubMedCentralPubMedCrossRef

37.

Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK (2013) Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. doi:10.1245/s10434-013-3276-z

38.

Liu Y, Yin W, Yan T, Du Y, Shao Z, Lu J (2013) The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature. Curr Med Res Opin. doi:10.1185/03007995.2013.833088

39.

Pathmanathan N, Balleine RL (2013) Ki67 and proliferation in breast cancer. J Clin Pathol 66(6):512–516. doi:10.1136/jclinpath-2012-201085 PubMedCrossRef

40.

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. doi:10.1056/NEJMra1001389 PubMedCrossRef

Titel: Complexity in Regulation of microRNA Machinery Components in Invasive Breast Carcinoma
verfasst von: Sun Young Kwon
Jae-ho Lee
Bora Kim
Jong-Wook Park
Taeg Kyu Kwon
Sun Hee Kang
Shin Kim
Publikationsdatum: 01.07.2014
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 3/2014
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9750-5

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Complexity in Regulation of microRNA Machinery Components in Invasive Breast Carcinoma

Abstract

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Characterization of the Attenuation of Breast Cancer Bone Metastasis in Mice by Zoledronic Acid Using 99mTc bone Scintigraphy

Polycomb Group Oncogene RING1 is Over-expressed in Non-Small Cell Lung Cancer

WT1 Overexpression Affecting Clinical Outcome in Non-Hodgkin Lymphomas and Adult Acute Lymphoblastic Leukemia

Hypoxia-Inducible Factor-1α and its Role in the Proliferation of Retinoblastoma Cells

Altered Expression of Multiple Genes Involved in Retinoic Acid Biosynthesis in Human Colorectal Cancer

Accurate Determination of the Pathological Stage with Gross Dissection Protocol for Radical Cystectomy

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie